Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.

Br J Cancer · 2019 · PMC6738041 · PMID 31296923

Europe PMC DOI

hedged sentence

0.5300

closest p · 10.6× alpha

0.5300

boldest claim

The sentences

a strong trendP = 0.53not close (p > 0.1)

When post-operative CEA was used as a categorical variable, a strong trend was observed between ≤5 and >5 ng/mL values and DFS, with the 3-year DFS rate of 86.6% and 75.5% in the ≤ 5 and > 5 ng/mL groups, respectively; P = 0.53.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.